



1 November 2021

**OMEGA DIAGNOSTICS GROUP PLC**  
**("Omega" or the "Company" or the "Group")**

**Exercise of Options and Total Voting Rights**

Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that it has agreed to allot in total 25,000 new ordinary shares of 4 pence each in the capital of the Company ("**Ordinary Shares**") following the exercise of share options under the 2007 EMI Share Option Scheme by certain option holders.

Application has been made to the London Stock Exchange for the 25,000 new Ordinary Shares to be admitted to trading on AIM ("**Admission**") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 9 November 2021.

After Admission, the total number of Ordinary Shares in issue will be 182,682,404 and the total number of voting rights will therefore be 182,682,404. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

**Contacts:**

**Omega Diagnostics Group PLC**

Colin King, Chief Executive  
Chris Lea, CFO

[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

via Walbrook PR

**finnCap Ltd**

Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane/Charlotte Sutcliffe (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus  
Lianne Cawthorne

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)

Mob: 07980 541 893

Mob: 07584 391 303